These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3918298)

  • 1. Efficacy of (D-Leu6)-des Gly-NH2 10-LHRH ethylamide against prostatic cancer.
    Yamanaka H; Makino T; Yajima H; Saruki K; Shida K
    Prostate; 1985; 6(1):27-34. PubMed ID: 3918298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide against prostatic cancer].
    Imai K; Kumasaka F; Kobayashi M; Suzuki T; Takahashi O; Yamanaka H
    Hinyokika Kiyo; 1985 Dec; 31(12):2302-6. PubMed ID: 2938456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The sustained release of LH X RH agonist from LH X RH agonist-polymer composite in patients with prostatic cancer.
    Imai K; Yamanaka H; Yuasa H; Yoshida M; Asano M; Kaetu I; Yamazaki I; Suzuki K
    Prostate; 1986; 8(4):325-32. PubMed ID: 3086853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LHRH ethylamide against prostatic cancer].
    Yamanaka H; Makino T; Kumasaka F; Shida K
    Hinyokika Kiyo; 1984 Apr; 30(4):545-60. PubMed ID: 6435416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.
    Warner B; Worgul TJ; Drago J; Demers L; Dufau M; Max D; Santen RJ
    J Clin Invest; 1983 Jun; 71(6):1842-53. PubMed ID: 6408125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testicular histology following chronic gonadotropin-releasing hormone agonist treatment.
    Rajfer J; Swerdloff RS; Heber DM
    Fertil Steril; 1984 Nov; 42(5):765-71. PubMed ID: 6436070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
    Niijima T; Aso Y; Akaza H; Fujita K; Fuse H; Hosaka M; Isurugi K; Kamidono S; Katayama T; Kawabe K
    Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
    Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
    Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.
    Santen RJ; Warner B
    Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
    Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
    Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term effects of administration of a gonadotropin-releasing hormone superagonist analog in men with prostatic carcinoma.
    Santen RJ; Demers LM; Max DT; Smith J; Stein BS; Glode LM
    J Clin Endocrinol Metab; 1984 Feb; 58(2):397-400. PubMed ID: 6420439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate.
    Smith JA; Glode LM; Wettlaufer JN; Stein BS; Glass AG; Max DT; Anbar D; Jagst CL; Murphy GP
    Urology; 1985 Feb; 25(2):106-14. PubMed ID: 3918369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
    Bélanger A; Labrie F; Dupont A; Brochu M; Cusan L
    Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine and clinical effects of leuprolide in prostatic cancer.
    Vance MA; Smith JA
    Clin Pharmacol Ther; 1984 Sep; 36(3):350-4. PubMed ID: 6432399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depot leuprolide acetate for treatment of precocious puberty.
    Parker KL; Lee PA
    J Clin Endocrinol Metab; 1989 Sep; 69(3):689-91. PubMed ID: 2503536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leuprolide versus diethylstilbestrol for metastatic prostate cancer.
    Leuprolide Study Group
    N Engl J Med; 1984 Nov; 311(20):1281-6. PubMed ID: 6436700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group.
    Sharifi R; Soloway M
    J Urol; 1990 Jan; 143(1):68-71. PubMed ID: 2104638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DES lead-in to use of luteinizing hormone releasing hormone analogs in treatment of metastatic carcinoma of prostate.
    Stein BS; Smith JA
    Urology; 1985 Apr; 25(4):350-3. PubMed ID: 3920802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary clinical evaluation of leuprorelin acetate depot injection in France, in the management of prostatic cancer.
    Navratil H
    J Int Med Res; 1990; 18 Suppl 1():69-73. PubMed ID: 2108887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gonadotropin and testosterone secretion in normal human males after stimulation with gonadotropin-releasing hormone (GnRH) or potent GnRH analogs using different modes of application.
    Happ J; Hartmann U; Weber T; Cordes U; Beyer J
    Fertil Steril; 1978 Dec; 30(6):666-73. PubMed ID: 365598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.